- ¥600
- Solarbio
- 北京
- IO02301
- 2026年08月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Store at -20℃，6 months.
- 保质期：
Store at -20℃，6 months.
- 英文名：
Oridonin(10mM in DMSO，Sterile)
- 库存：
999
- 供应商：
北京索莱宝科技有限公司
- CAS号：
28957-04-2
- 规格：
1ml
| CAS | 28957-04-2 |
| 中文名称 | 冬凌草甲素(10mM in DMSO，无菌） |
| 英文名称 | Oridonin(10mM in DMSO，Sterile) |
| 分子式 | C20H28O6 |
| 分子量 | 364.43 |
| 规格 | 1ml |
| 溶解性 | 请根据自己的实验要求使用。 |
| 外观(性状) | 无菌溶液 |
| 储存条件 | Store at -20℃，6 months. |
| 运输条件 | 冷冻运输 |
| EC | 631-100-8 |
| MDL | MFCD00221762 |
| SMILES | CC1(CC[C@@H]([C@]23[C@@H]1[C@@H]([C@]([C@]45[C@H]2CC[C@H]([C@H]4O)C(=C)C5=O)(OC3)O)O)O)C |
| InChIKey | SDHTXBWLVGWJFT-XKCURVIJSA-N |
| InChI | InChI=1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25，19(11，14(9)22)15(10)23)16(24)13(18)17(2，3)7-6-12(18)21/h10-13，15-16，21，23-25H，1，4-8H2，2-3H3/t10-，11-，12-，13+，15+，16-，18+，19-，20+/m0/s1 |
| PubChem CID | 5321010 |
| 靶点 | Akt |
| 通路 | PI3K/Akt/mTOR |
| 背景说明 | 是一种 AKT 抑制剂，具有抗肿瘤、抗菌、抗炎等生理活性，可用于相关研究。 |
| 生物活性 | Oridonin (NSC-250682)， a diterpenoid isolated from Rabdosia rubescens， acts as an inhibitor of AKT， with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor， anti-bacterial and anti-inflammatory effects.[1-2] |
| In Vitro | Oridonin is an ATP-competitive inhibitor of AKT with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2， respectively. Oridonin (5， 10 or 20 μM) obviously inhibits the growth of KYSE70， KYSE410 and KYSE450 ESCC cells via targeting AKT1/2. Oridonin (10 or 20 μM) causes G2/M phase cell cycle arrest in KYSE70， KYSE410 and KYSE450 cells， and induces apoptosis in these three cell lines at 20 μM. In addition， Oridonin (5， 10 or 20 μM) in combination with cisplatin or 5-FU enhances the inhibition of esophageal squamous cell carcinoma (ESCC) cell growth[1]. Oridonin (0.1 and 1 μM) preferentially suppresses AKT/mTOR signaling. Oridonin (1 μM) also selectively suppresses growth of breast cancer cells with hyperactivation of AKT signaling[2]. |
| In Vivo | Oridonin (160 mg/kg， p.o.) shows significant reduction in the tumor growth without obvious weigh loss in SCID mice bearing EG9 and HEG18 tumor cells. Oridonin treatment also suppresses the expression of Ki-67， phosphorylated AKT， GSK-3β or mTOR in mice[1]. Oridonin (15 mg/kg， i.p.) impairs cell growth in breast cancer with hyperactivation of AKT signaling in nude mice[2]. |
| 细胞实验 | Cells are seeded (6×103 cells/well for KYSE70; 2.5×103 cells/well for KYSE410; 2×103 cells/well for KYSE450) in 96-well plates and incubated for 24 h and then treated with different amounts of Oridonin or vehicle. After incubation for 24， 48 or 72 h， cell proliferation is measured by the MTT assay. For anchorage-independent cell growth assessment， cells (2.5， 5 or 10 μM Oridonin) suspended in complete medium are added to 0.3% agar with vehicle， 2.5， 5 or 10 μM Oridonin in a top layer over a base layer of 0.5% agar with vehicle， 2.5， 5 or 10 μM Oridonin. The cultures are maintained at 37°C in a 5% CO2 incubator for 3 weeks and then colonies are visualized under a microscope and counted using the Image-Pro Plus software program[1]. |
| 动物实验 | Mice[2] Breast cancer cells are harvested and resuspended in 40% Matrigel-Basement Membrane Matrix， LDEV-free， and then injected (100 μL per site) into the fourth pair of mammary fat pads of nude mice (CrTac: NCr-Foxn1nu). Tumors are measured in two dimensions using manual calipers. Tumor volume is calculated using the formula: Volume = 0.5 × length × width × width. Tumor volume is measured every 2-3 days. Upon harvesting， tumors are fixed in formalin overnight and then in 70% ethanol for histopathology analysis. Mice are treated with Oridonin (15 mg/kg) in 1% Pluronic F68 or vehicle (1% Pluronic F68) daily by intraperitoneal (IP) injection. BEZ235 is reconstituted 1:9 in 1-methyl-2 pyrolidone and polyethylene glycol 300 (PEG300) Mice are treated with this compound formulation at 45 mg/kg daily (QD) by oral gavage[2]. |
| 激酶实验 | For the AKT kinase assay， the ADP-Glo? Kinase Assay Kit is used. Active AKT1 or AKT2 kinase and inactive GSK-3β as substrate are mixed by 1× reaction buffer and then added to a white 96-well plate. Pure ATP provided in the kit is serially diluted obtain a final concentration of 0， 1， 10， 50， and 100 μM. GSK-3β is added to reach a final concentration of 2.5， 5， 10 or 20 μM and DMSO is used as a control. The mixed solution is incubated at room temperature and luciferase activity is measured using the Luminoskan Ascent plate reader[1]. |
| 数据来源文献 | [1]. Song M， et al. Targeting AKT with oridonin inhibits growth of esophageal squamous cell carcinoma in vitro and patient derived xenografts in vivo. Mol Cancer Ther. 2018 Apr 25. pii: molcanther.0823.2017. [2]. Sun B， et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018 Feb 1;9(35):23878-23889. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
商品化试剂和培养基均经过严格的质量控制以保证其无菌，但它们在操作过程中可能被污染。请遵循以下指导原则进行无菌操作，避免污染。请始终使用适当的灭菌方法（如高压灭菌器、除菌过滤器）对实验室中配制的任何试剂、培养基或溶液进行灭菌。 无菌操作 请始终用 70% 乙醇擦拭双手和工作区。 将容器、培养瓶、培养板和培养皿放入细胞培养通风橱之前，先用 70% 乙醇擦拭其外部。 不要直接从试剂瓶或培养瓶中倾倒培养基和试剂。 使用无菌玻璃或一次性塑料移液管和移液器操作液体时，每只移液管只能使用一次，以避免
培养基经高压灭菌后，用经过灭菌的工具（如接种针和吸管等）在无菌条件下接种含菌材料（如样品、菌苔或菌悬液等）于培养基上，这个过程叫做无菌接种操作。在实验室检验中的各种接种必须是无菌操作。 实验台面不论是什么材料，一律要求光滑、水平。光滑是便于用消毒剂擦洗；水平是倒琼脂培养基时利于培养皿内平板的厚度保持一致。在实验台上方，空气流动应缓慢，杂菌应尽量减少，其周围杂菌也应越少越好。为此，必须清扫室内，关闭实验室的门窗，并用消毒剂进行空气消毒处理，尽可能地减少杂菌的数量
工业级-DMSO用途： 主要用于无水有机化学合成反应和医药及中间体合成反应溶剂，使用该溶剂能提高化学反应速度，提高反应物的了收率，缩短反应时间，使合成反应变得更加顺利。 试剂级-DMSO用途: DMSO用作液体层析溶剂，同时用作测试物质紫外消光值上时用作参照物，存在于液体形态。 (责任编辑：大汉昆仑王)
技术资料暂无技术资料 索取技术资料
冬凌草甲素(10mM in DMSO，无菌)
¥600
